Ipsen Appoints Baxalta's Oncology Chief Meek CEO

Ipsen has appointed Baxalta's head of oncology David Meek as its new CEO, having formerly instigated a search in February. Baxalta's $32bn acquisition by Shire completed at the start of June.

David Meek's appointment as the new CEO of Ipsen is effective July 18, 2016. Ipsen began the search for a new CEO earlier this year when deputy CEO Christel Bories left the company due to "disagreements" with Ipsen's board over the group's strategy.

Ipsen then said it would split the role of chair and CEO into two positions. The chair/CEO role is currently...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip